PAR Paradigm Biopharmaceuticals Limited
Healthcare · Biotechnology
· website
$0.24
52wk 0.14 – 0.47
Overall
44.0
Value
76.9
Growth
56.2
Health
5.4
Quality
24.2
Momentum
55.3
Dividend
—
Price
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 0.0% |
| 1 month | 2.1% |
| 3 months | 40.0% |
| 6 months | 8.9% |
| 1 year | -30.0% |
| 3 years | -57.3% |
Risk
| Volatility (1y ann.) | 73.5% |
| Beta vs ASX 200 | 1.34 |
| Sharpe (1y) | -0.18 |
| VaR 95% (1-day) | -6.2% |
| Max drawdown (1y) | -68.9% |
| Off 1-year high | -45.6% |
Technicals
| RSI(14) | 67 |
| vs 50DMA | 14.1% |
| vs 200DMA | 6.5% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
76.9
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
—
Growth
56.2
Revenue growth (1y)
91
Revenue CAGR (3y)
22
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
5.4
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
18
Debt / Equity
0
Quality (Profitability & Cash Flow)
24.2
Return on equity
0
Return on assets
0
Operating margin
100
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
55.3
6-month return vs ASX 200
27
Price vs 200-day average
72
Price vs 50-day average
100
Position in 52-week range
33
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$153.48M
P/E (trailing)
—
P/E (forward)
1.35
EPS (trailing)
-0.15
Dividend yield
—
Payout ratio
0.0%
Beta
0.02
EV / EBITDA
-2.27
Price / Book
40.83
ROE
-457.0%
Operating margin
156,513.0%
Net margin
0.0%
Total cash
$15.44M
Total debt
$7.51M
Current ratio
1.10
Debt / Equity
2.16
Free cash flow
$-28.63M
Avg volume
1.99M
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$80.15K
- Gross profit$68.02K
- Operating income-$61.26M
- Net income-$56.33M
- Diluted EPS-0.15
- Free cash flow-$44.18M
- Net debt-$7.86M